INTRODUCTION
Breast cancer is the most commonly identified and one of the deadliest neoplasms in women in Western countries. The recent trend toward improvement in the breast cancer mortality rate is largely due to increased diagnosis of early stage disease, while our therapeutic options for advanced stage breast carcinomas are still fairly limited. Thus, there is a need to better understand the molecular basis of breast tumor progression and to use this knowledge for the design of targeted, molecularbased therapies. Recently developed technologies have enabled us to analyze molecular differences between normal and cancer cells at a genome-wide level in comprehensive and unbiased ways, allowing for the molecular-based classification of breast cancer and identification of gene signatures correlating with metastatic behavior and clinical outcome (1) . However, since most of these studies used bulk tissue composed of multiple cell types, the specific contribution of epithelial, myoepithelial, and various stromal cells to these tumor classifiers and prognostic signatures is unknown.
In past decades the major focus of cancer research has been the transformed tumor cell itself, while the role of the cellular microenvironment in tumorigenesis has not been widely explored.
Abbreviations used: SAGE, serial analysis of gene expression; DCIS, ductal carcinoma in situ; LOH, loss of heterozygosity; SMA, smooth muscle actin; MSDK, methylation specific digital karyotyping; CGH, comprehensive genomic hybridization; SNP, single nucleotide polymorphism.
Epithelial-mesenchymal interactions are known to be important for the normal development of the mammary gland and to play a role in breast tumorigenesis (2) (3) (4) (5) (6) (7) (8) (9) . Early studies demonstrated that the normal mammary microenvironment is capable of "reverting" the neoplastic phenotype of breast cancer cells by inducing cellular differentiation (10, 11) , suggesting that cancer cells can only thrive in a distorted environment or have to become independent of extracellular signals. The contribution of genetic host factors to tumor initiation, progression, and angiogenesis also support a role for nonepithelial cells in carcinogenesis (12, 13) . This was dramatically illustrated by the results that systemic inactivation of TGF-β type II receptor in stromal fibroblasts led to prostate and gastric epithelial neoplasia (14) , while its inactivation in mammary stromal fibroblasts led to abnormal ductal development and promoted the growth of transplanted tumors (15) . Similarly, a recent finding demonstrating that mammary tumors were only formed in carcinogen-treated cleared mammary fat pads of rats, regardless of whether the injected epithelial cells were exposed to carcinogens in vitro, also emphasizes the importance of stromal alterations in the initiating steps of breast cancer (16) . However, this finding could not be confirmed in mouse mammary glands where DMBA treatment of the stroma had no effect on mammary tumorigenesis (17) , suggesting differences among species or in experimental design. Numerous in vitro and in vivo studies using diverse experimental systems have demonstrated that the growth, survival, polarity, and invasive behavior of breast cancer cells can be modulated by myoepithelial and various stromal cells, and several genes have been implicated in this process (2) (3) (4) (5) (6) (7) (8) (9) (18) (19) (20) (21) (22) . In addition, certain histo-pathological features of breast tumors, including lymphocytic infiltration, fibrosis, and angio-and lymphangiogenesis, have proven prognostic significance. Despite these convincing data implicating a role for stromal cells in breast tumorigenesis, our understanding of the genes mediating cellular interactions and paracrine regulatory circuits among various cell types in normal and cancerous breast tissue and their role in breast tumorigenesis is limited. As a consequence of studies focusing almost exclusively on cancer cells, nearly all of the currently used cancer therapeutic agents target the cancer cells that, due to their inherent genomic instability, frequently acquire therapeutic resistance (23) . However, in part due to frequent therapeutic failures during the course of treatment of advanced stage tumors, increasing emphasis has been placed on targeting various stromal cells, particularly endothelial cells, via therapeutic interventions. Since these cells are thought to be normal and genetically stable, they are less likely to develop acquired resistance to cancer therapy. Thus, molecular targeting of the tumor microenvironment may be a novel promising option for cancer intervention and treatment.
Among all the cell types in the breast, myoepithelial cells have been one of the least analyzed, particularly compared to luminal epithelial cells (21, 24) . In this review we discuss the characteristics and normal function of myoepithelial cells and their putative role in breast tumor progression, including the hypothesis that myoepithelial cells are the key regulators of the in situ to invasive carcinoma transition and may be part of the stem cell niche. We mainly focus on the human mammary gland and breast carcinomas, although we also reference the studies using various model organisms.
THE IDENTITY OF MYOEPITHELIAL CELLS
The mammary gland is composed of multiple cell types, including luminal and myoepithelial cells, residing within the ducts and alveoli and various other cells located in the stroma (Fig. 1(A and B) ). In the ducts, myoepithelial cells form a nearly continuous layer of cells that surrounds the luminal epithelial cells and separates them from the basement membrane and the stroma, while in the alveoli, myoepithelial cells form a scaffold-like structure and some alveolar epithelial cells have direct contact with the basement membrane ( Fig. 1(A) ). Luminal epithelial and myoepithelial cells are differentiated using cell type-specific markers, many of which have been only fortuitously identified following immunohistochemical analysis of breast tissue ( Fig. 1(B) ). Myoepithelial cell-specific genes include smooth muscle actin (SMA), CD10/CALLA cell surface marker, calponin, cytokeratins 14 and 17 (CTK14 and CTK17), epidermal growth factor receptor (EGFR), and p63 (25) (26) (27) . In recent years several genome-wide unbiased studies were performed using various cell purification and profiling approaches to better characterize normal luminal epithelial or myoepithelial cells and identify additional genes specific for a particular cell lineage (28) (29) (30) (31) . One of these studies analyzed established myoepithelial cell lines and xenografts using Affymetrix arrays and compared them to normal and cancerous breast cell lines and primary tumors (28) . Using this approach the author identified numerous genes that distinguished myoepithelial cells from other cell types. Interestingly, many of these genes encode for extracellular matrix proteins (collagens, laminin A, fibronectin, osteonectin, etc.), proteins involved in angiogenesis (thrombospondin-1, plasminogen, etc.), and protease inhibitors (maspin, PAI-1, etc.), reconfirming the role of myoepithelial cells as tumor suppressors (28) . However, the gene expression profile of cell lines and xenografts may not faithfully reflect the in vivo patterns; therefore, profiling of uncultured cells is desirable for the discovery of cell lineagespecific markers. Along these lines proteomic analysis of uncultured purified normal luminal and myoepithelial cells identified 170 proteins differentially expressed between the two cell types, and 51 of these were annotated by tandem mass spectrometry (29) . Many of these corresponded to abundant cytoplasmic proteins, such as cytokeratins, intermediate filaments, and heat shock proteins. Another gene expression profiling study used serial analysis of gene expression (SAGE) to analyze freshly isolated, uncultured luminal epithelial and myoepithelial cells purified using BerEP4 and CD10 antibody coupled magnetic beads, respectively, from normal breast tissue (30) . This analysis revealed 295 genes statistically significantly differentially expressed between the two cell types, and identified 138 that were more abundant in myoepithelial cells. Interestingly a high fraction (43%) of the genes most highly specifically expressed in myoepithelial cells encode secreted or cell surface proteins, suggesting that myoepithelial cells are actively involved in autocrine/paracrine interactions ( Table I) .
All of these studies assumed that there is only one type of myoepithelial cell within the normal breast, but this is unlikely to be true, since not all myoepithelial cells express all myoepithelial markers, and myoepithelial cells localized in the ducts and alveoli may also be different. Therefore, additional analyses are necessary to further define the molecular portrait of the various normal myoepithelial cells.
THE ORIGIN OF MYOEPITHELIAL CELLS
The cell of origin of normal myoepithelial cells is not well defined. Understanding the normal development of the mammary gland, clarifying the relationships among stem cells and their differentiated progeny, and characterizing factors regulating these processes are important not only for furthering our knowledge of basic mammary gland biology, but also for improving our understanding of breast tumorigenesis. Human epidemiologic data indicate that exposure to various hormones, radiation and other environmental agents during intrauterine, infantile, or pubertal mammary gland development influence the subsequent incidence of breast cancer in adulthood (32) (33) (34) (35) . The development of the mammary gland is a complex process; contrary to that of most other organs it is completed only in adulthood and some aspects of cellular differentiation even require the completion of a full-term pregnancy, lactation, and involution cycle. The mammary gland is also unique with respect to being continuously remodeled following puberty due to the cyclical influence of reproductive hormones. Most of the available data on mammary gland development have been obtained in mice and interpreted for humans despite the wellknown differences between human and mouse mammary gland development and function. Studies analyzing the development of the human mammary gland have been limited to structural and immunohistochemical analyses of a small number of samples collected at different stages of fetal, infantile, childhood, and pubertal development (36) (37) (38) (39) . In the human embryo the breast bud arises as a result of proliferation of basal cells of the epidermis, and some markers of these basal keratinocytes are maintained (CTK19), while others are lost (CTK14) in the mammary epithelial cells, potentially due to factors secreted by the mesenchymal cells present in the breast bud (37) . Myoepithelial cell differentiation, as determined by the expression of myoepithelial cell-specific markers (SMA, CD10, p63, etc.) and the lack of expression of luminal cell markers (CTK19 etc.) seems to occur at 21-28 weeks of gestational age (38, 39 (41, 42) . Specifically, activation of the Notch pathway not only appears to enhance the proliferation of the putative mammary stem cells, but also increases the number of cells committed to the myoepithelial lineage by promoting the proliferation of bipotential or myoepithelial progenitor cells and enhancing myoepithelial differentiation. Further studies are needed to identify and characterize regulators of mammary stem cell proliferation and differentiation and determine how abnormal activity of these pathways may contribute to breast tumorigenesis.
THE FUNCTION OF MYOEPITHELIAL CELLS IN BREAST TUMOR PROGRESSION
Breast tumors evolve via sequential progression through defined clinical and pathologic stages starting with epithelial hyperproliferation, progressing into in situ, then invasive, and metastatic carcinomas (Fig. 2) . Ductal carcinoma in situ (DCIS) is believed to be the true precursor of invasive ductal carcinoma based on molecular-based clonality studies, its increased incidence in women with high risk of invasive breast cancer, its frequent coexistence with invasive lesions, and on its high rate of recurrence as an invasive tumor at its original site (43) (44) (45) (46) (47) (48) (49) . Until 1980, DCIS was diagnosed very rarely and represented less than 1% of all breast cancer cases. Due to the increased use of mammograms, DCIS became the most rapidly increasing subset of breast cancers and currently it accounts for 15-25% of newly diagnosed breast cancer cases in the United States (50, 51) . In contrast to the dramatic improvement in our ability to detect DCIS, our understanding of the pathophysiology of this disease and factors involved in its progression to invasive carcinoma are still poorly defined.
The major diagnostic criteria that pathologists use to differentiate in situ from invasive carcinomas is the presence or absence of an intact myoepithelial cell layer, which is usually confirmed by performing immunohistochemical analyses against myoepithelial cell-specific genes such as smooth muscle actin, p63, or CD10 (52) . However, it is unknown what leads to the disappearance of the myoepithelial cells in invasive tumors (selective elimination by apoptosis or disruption of normal myoepithelial cell differentiation from stem cells) and how this contributes to tumor progression. Exposure of myoepithelial cells in culture to even low concentrations of carrageenans, naturally occurring sulfated polysaccharides used in commercial food preparation, leads to cell death (53) . However, it is unknown if destruction of myoepithelial cells could occur by these compounds or by other environmental agents in human breast cancer patients.
The Tumor Suppressor Function of Myoepithelial Cells
Myoepithelial cells have been called natural tumor suppressors due to their inhibitory effect on various neoplastic phenotypes, including tumor cell growth, invasion, and angiogenesis (19) (20) (21) 24) . Myoepithelial cells also synthesize the basement membrane of the ducts and alveoli and form a structural barrier between the luminal epithelial cells and the surrounding stroma, thus, physically preventing tumor cell invasion. The tumor suppressor phenotype was identified based on the ability of myoepithelial cells to inhibit the growth and invasion of breast cancer cells in coculture assays in vitro and inhibit tumor growth in xenograft assays (19, 20, 54, 55) . These effects have been largely attributed to paracrine factors secreted by myoepithelial cells that exert their effects on the tumor epithelial cells. Some of these factors include ECM proteins, protease inhibitors, and various growth factors, but others are still unidentified. Most of these studies were performed using myoepithelial cell lines derived from benign or low-grade human myoepitheliomas of the breast, salivary gland, and bronchi (56) . Thus, these cells may not completely reflect the function of normal mammary epithelial cells. However, the myoepithelial cell lines used in these experiments are genetically fairly normal and have maintained the expression of all myoepithelial markers analyzed (SMA, S100A2, CTK14, etc.) even after prolonged passage in vitro, and the expression of all antitumorigenic genes was confirmed in primary human breast tissue by immunohistochemistry. In addition, the results were reproduced using freshly isolated primary normal mammary myoepithelial cells (57) . In these latter experiments coculturing normal breast myoepithelial cells (purified using anti-CD10/CALLA antibody) using transwell inserts with various human breast cancer cell lines led to decreased expression of MMPs (Matrix Metallo-proteases) in the cancer cells. This effect of the myoepithelial cells was observed even in the presence of cocultured fibroblasts, known promoters of tumor cell invasion, thus demonstrating the dominance of myoepithelial cells.
The antiinvasive and antiproliferative effects of myoepithelial cells can be further increased following treatment with tamoxifen due to the increased secretion of maspin and production of inducible nitric oxide synthase (iNOS), effects which are mediated by the estrogen receptor (58) . Although myoepithelial cells do not express estrogen receptor-α (ERα), they express ERβ both in vitro and in vivo (58, 59) , and the induction of maspin and iNOS appears to be mediated by ERβ-dependent activation of AP1. It remains to be determined if this effect of tamoxifen is also observed in breast cancer patients and if it contributes to the cancer preventative effects of antiestrogens.
In addition to being responsive to tamoxifen, mammary myoepithelial cells may also influence the response of luminal epithelial cells to estrogenic hormones, since they express high levels of steroid sulfatase (STS), a lysosomal hydrolyze that converts estrone 3-sulfate (E1S) and dehydroepiandrosterone-sulfate (DHEA-S) into their active, unsulfated forms (60) . The expression of STS in the myoepithelial cells may lead to increased local concentrations of these hormones, making them available for the ERα in luminal epithelial cells. However, this result has not been confirmed in vivo. Thus, the potential role of myoepithelial cells as regulators of the local concentration of estrogenic hormones remains to be determined.
Myoepithelial cells also influence the differentiation and polarity of the adjacent luminal epithelial cells. Luminal epithelial cells are polarized, as determined by the expression of the sialomucin MUC1, epithelial-specific antigen (ESA), and occludin on the luminal membrane and integrin β4 on the basolateral membrane. This polarity is observed in vitro when luminal epithelial cells are cultured in reconstituted basement membrane (matrigel), but lost when the cells are grown in collagen I (18) . However, mixing the luminal epithelial cells with normal myoepithelial cells was able to restore epithelial cell polarity even in collagen cultures; this effect was shown to be mediated by laminin-1. Interestingly myoepithelial cells isolated from invasive breast tumors were unable to exert this effect (18) . These tumor myoepithelial cells were isolated from primary breast carcinomas using a Thy-1 antibody column and were considered myoepithelial cells due to their emergence from luminal epithelial cells, expression of cytokeratins, vimentin, and SMA, and inability to form tumors in nude mice, but they were not analyzed for genetic changes and clonal relationship to the epithelial cells from the same tumor. Invasive breast tumors are by definition devoid of myoepithelial cells, but a subset of tumor cells, including the presumed "cancer stem cells," express high levels of Thy-1, vimentin, and cytokeratins. Similarly, stromal myofibroblasts are highly Thy-1 and vimentin positive, although they lack cytokeratins. Thus, the identity of these tumor cells with myoepithelial phenotype is somewhat of a mystery and would require further studies, although it is clear that they are not able to recapitulate the function of normal myoepithelial cells, presumably due to their lack of laminin-1 expression.
Alterations in Myoepithelial and Stromal Cells During Breast Tumor Progression
In the past few years the role of the cellular microenvironment in tumorigenesis has become an intense area of research. This is in part due to studies demonstrating that genetic abnormalities, such as loss of heterozygosity (LOH), occur not only in cancer cells, but in myoepithelial or stromal cells, or even normal-appearing epithelial cells surrounding the tumor and in benign stromal and epithelial hyperproliferative diseases (61) (62) (63) (64) (65) (66) (67) (68) (69) . In several cases the tumor epithelial and stromal cells had discordant genetic changes, suggesting a clonal coevolution for these two cell types. Due to the low probability of two adjacent cells simultaneously acquiring different genetic changes, the authors suggested that in some breast tumors epithelial and stromal cells may be derived from a common stem cell, but subsequently undergo divergent genetic selection processes. One study demonstrated discordant mutations in TP53 and PTEN in tumor epithelial and stromal cells, and a low frequency of WFDC1 mutations exclusively in the stromal cells (64) . However, no mechanistic insight was provided explaining the clonal selection for mutation in the same gene in the two different cellular compartments. Thus, the biological relevance of these mutations and LOH events in stromal cells and their role in breast tumorigenesis is still largely unknown. One potential problem with these studies is that the cellular identity of the stromal cells was not conclusively confirmed (e.g., by cell type-specific markers). Since they were isolated using laser capture microdissection (LCM) from formalinfixed and paraffin-embedded or frozen breast tumors, the possibility of contaminating tumor cells is difficult to rule out. Furthermore, due to the methods used, relatively few stromal cells were analyzed, and these were from a relatively small area of the tumor. Thus, it is uncertain if these LOH events reflect true clonally-selected genetic events that are observed in the majority of the tumor stroma or they are just random LOH that occur at low frequency in every dividing cell. Similarly, the report describing LOH in normal luminal and myoepithelial cells obtained from reduction mammoplasty specimens analyzed clones of cells expanded in in vitro cultures (70) . Thus, the possibility that the clone of a single cell expanded in vitro was analyzed or that the LOH occurred in vitro cannot be excluded.
Immunohistochemical analyses of normal breast tissue and in situ and invasive breast carcinomas aiming to identify markers of tumor progression using a candidate gene approach have identified several genes that are differentially expressed between normal and DCIS myoepithelial cells. Among others, lysyl oxidase, an enzyme involved in collagen and elastin crosslinking, was most highly expressed in myoepithelial cells and myofibroblasts in DCIS tumors (71) . Similarly, the expression of neuropilin-1 was found to be upregulated in DCIS myoepithelial and vascular smooth muscle cells compared to normal breast tissue and invasive carcinomas (72) . To identify molecular changes in the cellular microenvironment in an unbiased way, Allinen et al. purified and analyzed all cell types (epithelial, myoepithelial, and endothelial cells, infiltrating leukocytes, fibroblasts, and myofibroblasts) from normal breast tissue and in situ and invasive carcinomas and concluded that gene expression changes occur in all cell types during breast tumor progression, but clonally selected genetic changes are only observed in tumor epithelial cells (73) . In this study each cell type was purified using cell type-specific cell surface markers, and the purity of the isolated cell population was confirmed using RT-PCR and cell typespecific genes. The comprehensive gene expression profile of each purified cell population was then analyzed by SAGE, while genetic changes were analyzed by cDNA array comprehensive genomic hybridization (CGH) and single nucleotide polymorphism (SNP) arrays. Interestingly, the comparison of myoepithelial cells from normal breast tissue and DCIS yielded the highest number of consistently differentially expressed genes, and a significant fraction of these encoded for secreted and cell surface proteins, including several chemokines (Tables I and II) . Many of the genes specific for normal myoepithelial cells (CTK14, CTK17, OXTR, EGFR, etc.) were absent or dramatically downregulated in DCIS myoepithelial cells, suggesting that myoepithelial cells in DCIS are not really "normal" since they appear to be less differentiated and likely have lost some of the functions of normal myoepithelial cells (Tables I and II). However, demonstrating functional differences between normal and DCIS myoepithelial cells and demonstrating that these changes play a role in breast tumor progression require further studies.
The dramatic gene expression changes and lack of genetic alterations in the tumor myoepithelial and stromal cells suggested underlying epigenetic changes, since cells isolated from normal and tumor tissue are known to maintain their differences even after prolonged cell culture in vitro (4, 9, 74, 75) . Indeed, a followup study by Hu et al. using a newly developed method (MSDK: methylation-specific digital karyotyping) for the analysis of genome-wide methylation profiles identified alterations in DNA methylation patterns not only in tumor epithelial cells but Note. SAGE tag sequence (Tag), normalized tag numbers in normal (NM) and DCIS (DM) myoepithelial cells, and in myofibroblasts (MF), their ratios, and the subcellular localization of the encoded protein are listed. Genes were selected as described in Table 1 .
also in stromal fibroblasts and DCIS myoepithelial cells as well (76) . Consistent with prior results, increased DNA methylation in the promoter region of the genes negatively correlated with gene expression, while hypermethylation of introns and 3 exons positively influenced gene expression, suggesting the presence of silencer/insulator elements that are regulated by DNA methylation (76, 77) . The best characterized example for this phenomenon is the imprinting of the H19/IGF2 genes that are regulated by a silencer/insulator containing a binding site for CTCF (78, 79) . The imprinting of IGF2 is dependent on CTCF binding to this enhancer-blocking element, and its methylation inhibits CTCF binding and leads to loss of imprinting (78, 79) . Interestingly, based on their sequences, two of the differentially methylated genes identified by Hu et al. appear to have a consensus CTCF binding site in their hypermethylated region, but demonstrating their silencer function requires followup studies.
The Relationship Between Myoepithelial Cells and Myofibroblasts
Close "relatives" of myoepithelial cells are the myofibroblasts, since they share the expression of many genes, including SMA, Thy-1, vimentin, CD10/CALLA, and several proteases and protease inhibitors (73) . However, myoepithelial cells express cytokeratins and are located within the breast ducts, while myofibroblasts are mesenchymal cells located in the stroma. The cell of origin of myofibroblasts is still subject to debate, with two main hypotheses dominating. According to one model myofibroblasts are fibroblasts "transformed" by TGFβ and PDGF possibly secreted by the tumor cells or infiltrating leukocytes, since treatment of fibroblasts in in vitro cultures with these growth factors leads to the expression of SMA and other myofibroblast-specific genes (80, 81) . However, in vivo studies performed both in mice and humans provide strong evidence that myofibroblasts are derived from circulating mesenchymal stem cells recruited to the tumors either by the tumor cells themselves or by the inflammatory reaction initiated by infiltrating leukocytes (82, 83) . Despite the similarity of gene expression patterns between myoepithelial cells and myofibroblasts, it is unlikely that the two cell types are clonally related. Correlating with this idea, comprehensive analysis of their gene expression profiles identified many genes differentially expressed between the two cell types (Table II) . A significant fraction (49%) of these genes encode secreted and cell surface proteins, including chemokines, ECM molecules, proteases and protease inhibitors, implicating both cells in autocrine/paracrine interactions and ECM remodeling. The hypothesis that myoepithelial cells may become myofibroblasts during the in situ to invasive carcinoma transition is unlikely, but deserves further investigation.
Models of Breast Tumor Progression
Our fairly limited understanding of the in situ to invasive carcinoma transition is in part due to the fact that there are no good experimental models for DCIS that faithfully reproduce the human disease. Carcinogen-induced mammary gland tumors in rats reproduce certain aspects of human DCIS, such as ovarian hormone dependence and gradual progression to invasive disease (84) . However, the carcinogen used for the initiation of these tumors may have caused numerous genetic changes that are not easy to identify, making this model unattractive for molecular studies addressing the role of specific genes in mammary tumorigenesis. Similar limitations apply to the use of DCIS xenografts formed by subcutaneous injection of pieces of human DCIS tumors into nude mice (85) .
Although no model is ideal, an appropriate model should allow the functional testing of genes implicated in breast cancer and the evaluation of novel cancer preventive and therapeutic interventions. A good model of DCIS would have to resemble the histology of high-risk human premalignant breast lesions that with time progress to invasive carcinomas. The MCF10AT human breast cell line is one of the most well-characterized human models of breast tumor progression that fulfills these criteria (86, 87) . These cells were derived from the immortalized MCF-10A cells via transformation with T24 mutant c-Ha-ras (86, 87) . Interestingly, the MCF10AT cells appear to contain multipotent (or bipotential) breast stem cells, since both luminal epithelial and myoepithelial cells can be derived from these cells in vivo (88) . Recently a derivative of the MCF10AT premalignant human cell line model was established, the MCF10DCIS.com cells, that reproducibly form comedo DCIS-like lesions which spontaneously progress to invasive tumors (86, 87) . Therefore, the MCF10DCIS.com model could potentially be used for analyzing the role of myoepithelial cells in breast tumor progression.
However, just because a tumor looks like a DCIS does not mean that it is "really" a DCIS, and cells expressing myoepithelial markers may not always be "real" myoepithelial cells. This problem is illustrated by the detection of "revertant" DCIS in lymph nodes of some breast cancer patients with metastatic breast tumors (89) . Specifically, a subset of invasive or metastatic breast tumors demonstrate a DCIS-like growth pattern as determined by cells growing in tight clusters surrounded by basement membrane, but these structures lack a myoepithelial cell layer, emphasizing the importance of staining for myoepithelial cell-specific markers in cases of questionable diagnosis. Similarly, in invasive breast tumors with a basal phenotype, the tumor cells themselves express several genes normally detected in myoepithelial cells, including p63 and cytokeratin 14, presumably because these tumors originate from bipotential progenitor cells and show some degree of myoepithelial differentiation (90) . However, multiple myoepithelial markers such as smooth muscle actin, smooth muscle myosin heavy chains, and calponin are very rarely coexpressed within the same tumor cell. Thus, to conclusively prove that a cell is a normal terminally differentiated myoepithelial cell, the examination of multiple markers is necessary.
The "Escape" or "Release" Model of In Situ to Invasive Carcinoma Transition
The prevailing view of breast tumor progression is tumor epithelial cell-driven, since tumor epithelial cells have acquired genetic changes and demonstrate genomic instability and the most aggressive invasive cells can be selected out due to clonal selection. However, this model has recently been challenged by multiple independent studies. First, demonstrating genetic changes in tumor stroma, although still controversial, raises the possibility that clonal selection occurs in nonepithelial cells as well. Thus, the microenvironment may play an active role in driving tumor progression. Second, identification of global gene expression changes and epigenetic alterations in all cell types during breast tumor progression and the finding that the genetic background of the host influences metastatic behavior suggest that tumorigenesis is a "team effort." Although genetic changes may only occur in tumor epithelial cells, changes in the cellular microenvironment are likely to play a role in tumor progression. Studies demonstrating increased cancer risk in patients with chronic inflammatory disease and decreased risk in users of antiinflammatory drugs plus experiments performed in model systems addressing the role of genetically modified stroma in tumorigenesis (91) , raise the possibility that alterations in the microenvironment play a role even in tumor initiation.
Based on these data we propose two alternative models of the in situ to invasive carcinoma transition (Fig. 3) . One hypothesis emphasizes the role of tumor epithelial cells and suggests that genetic changes in these cells lead to the selection of a clone with invasive properties that will "escape" from the duct, spread into the stroma, and subsequently expand. The second model gives more credit to the nonepithelial cells and implies that phenotypic changes in DCIS myoepithelial cells, and accumulation of inflammatory cells and myofibroblasts work together and lead to the break down of the ducts and results in the "release" of tumor epithelial cells. Recently published studies describing focal myoepithelial cell layer disruption in DCIS breast tumors at sites of leukocytic infiltration give support to the "release" model (92) . Similarly, experiments performed using the MCF10DCIS.com model system suggest that myoepithelial cells play a key role in the regulation of in situ to invasive carcinoma transition (Hu et al., unpublished data). However, the two models are not mutually exclusive. For example, it is possible that factors secreted by DCIS myoepithelial cells, infiltrating leukocytes, and myofibroblasts may influence the clonal evolution of the tumor epithelial cells. Supporting this combined view is the finding that tumor epithelial cells overlaying sites of focally disrupted myoepithelial cell layers are phenotypically and genetically different from their adjacent counterparts (92) . These cells are potentially responsible for the subsequent progression of the tumors; thus, they may be the putative "cancer stem cells." This scenario raises the question whether paracrine factors secreted by myoepithelial and stromal cells may influence the cancer stem cell phenotype. Thus, cells of the tumor microenvironment may constitute the stem cell niche, a hypothesis worth investigating in the future. Of course it is difficult to know what comes first, the development of a genetically distinct tumor epithelial cell clone or the myoepithelial cell layer disruption. Clarifying this "chicken or egg" dilemma will likely to keep investigators busy for years to come. 
CONCLUSIONS
Due to decades of neglect, the function of mammary myoepithelial cells and their role in breast tumorigenesis is still largely unknown. However, recent and emerging studies implicate them as potential regulators of the in situ to invasive carcinoma transition and stem cell function. In light of the importance of these issues, myoepithelial cells are now the focus of intense investigations. By understanding their functions, we are likely to gain new, valuable targets for breast cancer prevention and treatment.
ACKNOWLEDGMENTS
We greatly appreciate the generosity of Drs. 
